Table of Content

Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Technological Advances
Conclusion

Chapter 2 Market Overview
Overview
Biologic and Synthetic Drug Comparison
Biologic Manufacturing
Biopharmaceutical Manufacturing Process
Macroeconomic Factors Analysis
Porter’s Five Forces Analysis
Supply Chain Analysis
Cell and Gene Therapy Supply Chain

Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Growing Demand for Biologics
Rising Investments in Biopharmaceuticals
Product Development Collaborations and Agreements
Transition Toward Personalized Medicines
Rising Aging Population and the Growing Prevalence of Chronic Diseases
Market Restraints
Emergence of Biosimilars
Complex Manufacturing, Lack of Skilled Professionals and High Production Costs
Market Opportunities
Rising Demand for Biopharmaceuticals in Emerging Countries
Technological Innovations in Biologics

Chapter 4 Regulatory Landscape
U.S. Approval Process
European Union Approval Process
Asia-Pacific Approval Process

Chapter 5 Emerging Technologies and Developments
Emerging Technologies
Advances in Monoclonal Antibodies
Antibody-Drug Conjugates
Bispecific Antibodies
Nanobodies
Single-Chain Variable Fragments Antibodies
Antibody Mimetics
Antibody Fusion Proteins
Advances in Vaccines
Advances in Cell and Gene Therapies

Chapter 6 Market Segmentation Analysis
Overview
Segmentation Breakdown
Market Analysis by Product Type
Monoclonal Antibodies
Vaccines
Peptide Hormones
Cell and Gene Therapy
Others
Market Analysis by Source Type
Mammalian
Microbial
Others
Market Analysis by Application
Oncology
Autoimmune Disease
Infectious Diseases
Others
Geographic Breakdown
Market Analysis by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 7 Competitive Intelligence
Overview
Highest Selling Biologic Therapeutic Drugs
Market Share Analysis
Monoclonal Antibodies
Vaccines
Peptide Hormones
Cell and Gene Therapy
Strategic Initiatives
Agreements, Collaborations and Partnerships
Acquisitions
Other Strategies

Chapter 8 Sustainability in Biologics Therapeutic Drug Market: An ESG Perspective
Introduction to ESG
Sustainability Trends and Initiatives
Environmental
Social and Governance Initiatives
ESG Risk Ratings
Concluding Remarks

Chapter 9 Appendix
Research Methodology
Emerging Start-ups/Market Disruptors
Sources
Abbreviations
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
ELI LILLY AND CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GSK PLC.
JOHNSON & JOHNSON SERVICES INC.
MERCK & CO. INC.
NOVARTIS AG
NOVO NORDISK A/S
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI



List of Figures

 

Summary Figure : Global Market Shares of Biologic Therapeutic Drugs, by Region, 2023
Figure 1 : Differences Between Synthetic and Biologic Drugs
Figure 2 : Porter’s Five Forces Analysis of the Biologic Therapeutic Drugs Market
Figure 3 : Supply Chain of Biopharmaceutical Drugs
Figure 4 : Market Dynamics of Biologic Therapeutic Drugs
Figure 5 : Venture Averages for Biopharma Therapeutics and Platform Companies, 2010–2024
Figure 6 : Personalized Medicines’ Contribution to the Total FDA Approvals, 2015–2023
Figure 7 : Emerging Technologies in Monoclonal Antibodies
Figure 8 : Global Market Shares of Biologic Therapeutic Drugs, by Product Type, 2023
Figure 9 : Global Vaccination Coverage, by Vaccine, 2023
Figure 10 : Global Market Shares of Biologic Therapeutic Drugs, by Source Type, 2023
Figure 11 : Global Market Shares of Biologic Therapeutic Drugs, by Application Type, 2023
Figure 12 : Global Market Shares for Biologic Therapeutic Drugs, by Region, 2023
Figure 13 : North American Market Shares of Biologic Therapeutic Drugs, by Country, 2023
Figure 14 : European Market Shares of Biologic Therapeutic Drugs, by Country, 2023
Figure 15 : Asia-Pacific Market Shares of Biologic Therapeutic Drugs, by Country, 2023
Figure 16 : Rest of the World Market Shares of Biologic Therapeutic Drugs, by Sub-Region, 2023
Figure 17 : Top 10 Blockbuster Biologic Therapeutic Drugs, by Sales Revenue, 2023
Figure 18 : Global Market Shares for Monoclonal Antibodies, by Key Players, 2023
Figure 19 : Global Market Shares for Vaccines, by Key Players, 2023
Figure 20 : Global Market Shares for Peptide Hormones, by Key Players, 2023
Figure 21 : Global Market Shares for Cell and Gene Therapy, by Key Players, 2023
Figure 22 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
Figure 23 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
Figure 24 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
Figure 25 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
Figure 26 : AstraZeneca: Revenue Share, by Business Unit, FY 2024
Figure 27 : AstraZeneca: Revenue Share, by Region/Country, FY 2024
Figure 28 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
Figure 29 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
Figure 30 : Eli Lilly and Co.: Revenue Share, by Business Unit, FY 2024
Figure 31 : Eli Lilly and Co.: Revenue Share, by Country/Region, FY 2024
Figure 32 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 33 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 34 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2024
Figure 35 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2024
Figure 36 : GSK PLC.: Revenue Share, by Business Unit, FY 2024
Figure 37 : GSK PLC.: Revenue Share, by Country/Region, FY 2024
Figure 38 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2024
Figure 39 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2024
Figure 40 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2024
Figure 41 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2024
Figure 42 : Novartis AG: Revenue Share, by Business Unit, FY 2024
Figure 43 : Novartis AG: Revenue Share, by Country/Region, FY 2024
Figure 44 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2024
Figure 45 : Novo Nordisk A/S: Revenue Share by Country/Region, FY 2024
Figure 46 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
Figure 47 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
Figure 48 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
Figure 49 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2024
Figure 50 : Sanofi: Revenue Share, by Business Unit, FY 2024
Figure 51 : Sanofi: Revenue Share, by Country/Region, FY 2024

List of Tables

 

Summary Table : Global Market for Biologic Therapeutic Drugs, by Region, Through 2029
Table 1 : Global Incidence and Mortality Cancer Rates, by the WHO Region, 2022
Table 2 : Global Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 3 : Top-Selling Monoclonal Antibodies, in 2023
Table 4 : Global Market for Monoclonal Antibodies, by Region, Through 2029
Table 5 : Global Market for Vaccines, by Region, Through 2029
Table 6 : Global Market for Peptide Hormones, by Region, Through 2029
Table 7 : Cell and Gene Therapy Approvals, 2023 and 2024
Table 8 : Global Market for Cell and Gene Therapy, by Region, Through 2029
Table 9 : Global Market for Other Biologic Drugs, by Region, Through 2029
Table 10 : Global Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 11 : Global Market for Mammalian Cells, by Region, Through 2029
Table 12 : Global Market for Microbial Cells, by Region, Through 2029
Table 13 : Global Market for Other Cells, by Region, Through 2029
Table 14 : Global Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 15 : Global Market for Biologic Therapeutic Drugs in Oncology, by Region, Through 2029
Table 16 : Global Market for Biologic Therapeutic Drugs for Autoimmune Diseases, by Region, Through 2029
Table 17 : Global Market for Biologic Therapeutic Drugs for Infectious Diseases, by Region, Through 2029
Table 18 : Global Market for Biologic Therapeutic Drugs for Other Diseases, by Region, Through 2029
Table 19 : Global Market for Biologic Therapeutic Drugs, by Region, Through 2029
Table 20 : North American Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 21 : North American Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 22 : North American Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 23 : North American Market for Biologic Therapeutic Drugs, by Country, Through 2029
Table 24 : FDA-Approved Biologics, 2023
Table 25 : European Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 26 : European Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 27 : European Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 28 : European Market for Biologic Therapeutic Drugs, by Country, Through 2029
Table 29 : Asia-Pacific Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 30 : Asia-Pacific Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 31 : Asia-Pacific Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 32 : Asia-Pacific Market for Biologic Therapeutic Drugs, by Country, Through 2029
Table 33 : Biologics Approved in China, in 2023
Table 34 : Rest of the World Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 35 : Rest of the World Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 36 : Rest of the World Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 37 : Rest of the World Market for Biologic Therapeutic Drugs, by Sub-Region, Through 2029
Table 38 : Agreements, Collaborations and Partnerships in the Biologic Therapeutic Drug Market, 2022-2025
Table 39 : Acquisitions in the Biologic Therapeutic Drug Market, 2022-2024
Table 40 : Others Strategic Initiatives in the Biologic Therapeutic Drug Market, 2022-2024
Table 41 : Environmental Initiatives by Various Biologic Therapeutic Drug Manufacturers
Table 42 : Key Social and Governance Issues Biologic Therapeutic Drug Market
Table 43 : ESG Risk Rankings for Biologic Therapeutic Drug Companies, 2023
Table 44 : List of a Few Emerging Startups in the Biologic Therapeutic Drugs Market
Table 45 : Information Sources in this Report
Table 46 : Abbreviations Used in the Global Biologic Therapeutic Drugs Market
Table 47 : AbbVie Inc.: Company Snapshot
Table 48 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 49 : AbbVie Inc.: Product Portfolio
Table 50 : AbbVie Inc.: News/Key Developments, 2022–2024
Table 51 : Amgen Inc.: Company Snapshot
Table 52 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 53 : Amgen Inc.: Product Portfolio
Table 54 : Amgen Inc.: News/Key Developments, 2021-2024
Table 55 : AstraZeneca: Company Snapshot
Table 56 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 57 : AstraZeneca: Product Portfolio
Table 58 : AstraZeneca: News/Key Developments, 2021?2024
Table 59 : Bristol-Myers Squibb Co.: Company Snapshot
Table 60 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 61 : Bristol-Myers Squibb Co.: Product Portfolio
Table 62 : Bristol-Myers Squibb Co.: News/Key Developments, 2022–2025
Table 63 : Eli Lilly and Co.: Company Snapshot
Table 64 : Eli Lilly and Co.: Financial Performance, FY 2023 and 2024
Table 65 : Eli Lilly and Co.: Product Portfolio
Table 66 : Eli Lilly and Co.: News/Key Developments, 2023 and 2024
Table 67 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 68 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 69 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 70 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022–2025
Table 71 : Gilead Sciences Inc.: Company Snapshot
Table 72 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 73 : Gilead Sciences Inc.: Product Portfolio
Table 74 : Gilead Sciences Inc.: News/Key Developments, 2022?2024
Table 75 : GSK PLC.: Company Snapshot
Table 76 : GSK PLC.: Financial Performance, FY 2023 and 2024
Table 77 : GSK PLC.: Product Portfolio
Table 78 : GSK PLC.: News/Key Developments, 2024
Table 79 : Johnson & Johnson Services Inc.: Company Snapshot
Table 80 : Johnson & Johnson Services Inc.: Financial Performance, FY 2023 and 2024
Table 81 : Johnson & Johnson Services Inc.: Product Portfolio
Table 82 : Johnson & Johnson Services Inc.: News/Key Developments, 2022?2024
Table 83 : Merck & Co. Inc.: Company Snapshot
Table 84 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 85 : Merck & Co. Inc.: Product Portfolio
Table 86 : Merck & Co. Inc.: News/Key Developments, 2022–2024
Table 87 : Novartis AG: Company Snapshot
Table 88 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 89 : Novartis AG: Product Portfolio
Table 90 : Novartis AG: News/Key Developments, 2022-2025
Table 91 : Novo Nordisk A/S: Company Snapshot
Table 92 : Novo Nordisk A/S: Financial Performance, FY 2023 and 2024
Table 93 : Novo Nordisk A/S: Product Portfolio
Table 94 : Novo Nordisk A/S: News/Key Developments, 2021–2025
Table 95 : Pfizer Inc.: Company Snapshot
Table 96 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 97 : Pfizer Inc.: Product Portfolio
Table 98 : Pfizer Inc.: News/Key Developments, 2023–2024
Table 99 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 100 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 101 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 102 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2024
Table 103 : Sanofi: Company Snapshot
Table 104 : Sanofi: Financial Performance, FY 2023 and 2024
Table 105 : Sanofi: Product Portfolio
Table 106 : Sanofi: News/Key Developments, 2022–2024